Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Sector Analysis

Pharmaceutical Preparations

Standard Industrial Classification: SIC 2834

Industry Insider Sentiment Analysis

The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.

Filing Date Trade Date Ticker Company Reporting Person Relationship Type Price Qty Total, $ Owned After
2025-08-12 01:12 2025-08-07 BBIO BridgeBio Pharma, Inc. Kumar Neil Director, Officer SELL $45.84 80,000 $3,666,952 915,686
2025-08-12 01:51 2025-08-07 ELVN Enliven Therapeutics, Inc. Patel Anish Officer SELL $18.24 6,667 $121,615 289,975
2025-08-12 00:07 2025-06-17 BYSI BeyondSpring Inc. Decheng Capital China Life Sciences USD Fund III, L.P. 10% owner SELL $3.05 394,436 $1,204,055 891,734
2025-08-11 23:35 2025-08-11 RPRX Royalty Pharma plc Norden Gregory Director SELL $36.23 33,500 $1,213,749 194,848
2025-08-11 23:09 2025-08-07 PCRX Pacira BioSciences, Inc. BIGAL MARCELO Director SELL $23.67 4,912 $116,267 11,393
2025-08-11 16:12 2025-07-01 CPIX CUMBERLAND PHARMACEUTICALS INC Young Caroline Director BUY $3.44 168 $578 32,821
2025-08-11 16:00 2025-07-01 CPIX CUMBERLAND PHARMACEUTICALS INC Jones James Director BUY $3.43 340 $1,166 43,676
2025-08-11 15:39 2025-07-01 CPIX CUMBERLAND PHARMACEUTICALS INC Krogulski Kenneth Director BUY $3.43 1,712 $5,872 288,345
2025-08-11 15:50 2025-07-01 CPIX CUMBERLAND PHARMACEUTICALS INC KAZIMI A J Director, Officer, 10% owner BUY $3.43 340 $1,166 5,699,768
2025-08-08 22:13 2025-08-07 GOVX GeoVax Labs, Inc. McKee Kelly T. Jr. Officer BUY $0.67 1,107 $742 3,494
2025-08-08 23:30 2025-08-07 NUVL Nuvalent, Inc. Pelish Henry E. Officer OPT+S $74.85 5,500 $411,675 60,956
2025-08-08 23:50 2025-08-07 MIRM Mirum Pharmaceuticals, Inc. Howe Jolanda Officer OPT+S $58.00 10,000 $580,000 2,426
2025-08-08 23:35 2025-08-06 KNSA Kiniksa Pharmaceuticals International, plc Paolini John F. Officer OPT+S $32.55 29,325 $954,529 57,403
2025-08-08 23:49 2025-08-07 MIRM Mirum Pharmaceuticals, Inc. Peetz Christopher Director, Officer OPT+S $55.25 40,000 $2,210,040 138,641
2025-08-08 23:20 2025-08-08 LLY ELI LILLY & Co JACKSON JAMERE Director BUY $639.56 200 $127,913 9,402
2025-08-09 00:45 2025-08-06 RNA Avidity Biosciences, Inc. Mosbrooker Eric Officer OPT+S $44.06 130,807 $5,763,697 55,000
2025-08-09 00:39 2025-08-06 RNA Avidity Biosciences, Inc. Hughes Steven George Officer OPT+S $42.74 81,434 $3,480,269 38,867
2025-08-09 00:42 2025-08-06 RNA Avidity Biosciences, Inc. WILSON TROY EDWARD Director OPT+S $45.00 95,054 $4,277,430 17,776
2025-08-08 18:45 2025-08-08 PRGO PERRIGO Co plc Lockwood-Taylor Patrick Director, Officer BUY $22.37 4,460 $99,766 85,812
2025-08-08 23:56 2025-08-08 OPK OPKO HEALTH, INC. FROST PHILLIP MD ET AL Director, Officer, 10% owner BUY $1.32 675,000 $891,000 214,676,448
2025-08-08 23:40 2025-08-06 SUPN SUPERNUS PHARMACEUTICALS, INC. Khattar Jack A. Director, Officer OPT+S $42.02 140,000 $5,883,360 1,069,933
2025-08-08 23:05 2025-08-07 VNDA Vanda Pharmaceuticals Inc. Polymeropoulos Mihael Hristos Director, Officer BUY $4.15 10,000 $41,500 2,335,731
2025-08-09 00:41 2025-08-06 RNA Avidity Biosciences, Inc. LEVIN ARTHUR A Director OPT+S $47.62 107,500 $5,118,881 19,650
2025-08-08 23:31 2025-08-07 UTHR UNITED THERAPEUTICS Corp MAHON PAUL A Officer OPT+S $300.00 11,000 $3,299,980 36,781
2025-08-09 01:55 2025-08-06 IONS IONIS PHARMACEUTICALS INC PARSHALL B LYNNE Director SELL $41.93 5,000 $209,646 86,344
2025-08-07 16:00 2025-08-05 AKRO Akero Therapeutics, Inc. Rolph Timothy Officer OPT+S $49.30 12,500 $616,299 167,124
2025-08-07 23:50 2025-08-05 BBIO BridgeBio Pharma, Inc. Ellis Andrea Director OPT+S $49.00 17,167 $841,183 18,589
2025-08-07 23:23 2025-08-06 VRTX VERTEX PHARMACEUTICALS INC / MA Kewalramani Reshma Director, Officer BUY $389.58 10,000 $3,895,768 115,968
2025-08-07 23:40 2025-08-05 KNSA Kiniksa Pharmaceuticals International, plc Tessari Eben Officer OPT+S $33.20 138,614 $4,602,373 49,915
2025-08-07 23:30 2025-08-05 LQDA Liquidia Corp Kaseta Michael Officer SELL $20.00 30,000 $600,132 376,412
2025-08-08 03:00 2025-08-05 WVE Wave Life Sciences Ltd. TAKANASHI KEN Director SELL $8.75 4,872 $42,630 5,716,303
2025-08-08 03:00 2025-08-05 WVE Wave Life Sciences Ltd. Tan Aik Na Director SELL $8.75 1,127 $9,861 14,988
2025-08-08 00:00 2025-08-05 IRON Disc Medicine, Inc. Bitterman Kevin Director SELL $60.95 395 $24,075 625,082
2025-08-08 00:00 2025-08-05 ABBV AbbVie Inc. Donoghoe Nicholas Officer SELL $198.51 13,295 $2,639,253 58,247
2025-08-07 23:19 2025-08-06 VRTX VERTEX PHARMACEUTICALS INC / MA SACHS BRUCE I Director BUY $389.68 5,000 $1,948,416 45,000
2025-08-08 02:17 2025-08-05 CORT CORCEPT THERAPEUTICS INC Guyer William Officer OPT+S $71.77 14 $1,005 5,487
2025-08-07 23:15 2025-08-05 AIMD Ainos Inc. Taiwan Carbon Nano Technology Corp 10% owner SELL $2.77 31,191 $86,249 1,048,912
2025-08-06 23:30 2025-08-04 KNSA Kiniksa Pharmaceuticals International, plc Ragosa Mark Officer OPT+S $32.89 18,889 $621,259 27,009
2025-08-07 03:38 2025-08-06 VSTM Verastem, Inc. Paterson Dan Director, Officer SELL $5.81 1,332 $7,739 442,507
2025-08-06 23:30 2025-08-04 KNSA Kiniksa Pharmaceuticals International, plc Megna Michael R Officer OPT+S $32.35 17,000 $549,950 33,041
2025-08-07 01:44 2025-08-05 IONS IONIS PHARMACEUTICALS INC Geary Richard S Officer SELL $42.86 10,000 $428,593 89,492
2025-08-07 00:22 2025-08-04 SER Serina Therapeutics, Inc. Moreadith Randall Officer OPT+S $5.17 5,500 $28,435 0
2025-08-06 23:19 2025-08-04 INSM INSMED Inc Flammer Martina M.D. Officer OPT+S $109.50 8,715 $954,293 83,111
2025-08-06 23:21 2025-08-04 INSM INSMED Inc Lewis William Director, Officer OPT+S $109.81 6,830 $750,008 233,924
2025-08-05 23:04 2025-08-01 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD Jover Placid Officer OPT+S $15.16 6,053 $91,748 6,774
2025-08-05 23:02 2025-08-01 TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD Hughes Eric A Officer OPT+S $15.16 52,742 $799,437 0
2025-08-06 00:28 2025-08-04 IONS IONIS PHARMACEUTICALS INC Schneider Eugene Officer SELL $42.80 9,549 $408,701 51,507
2025-08-06 01:29 2025-08-04 ARQT Arcutis Biotherapeutics Inc. Watanabe Todd Director, Officer SELL $14.33 11,547 $165,429 901,569
2025-08-06 01:28 2025-08-04 ARQT Arcutis Biotherapeutics Inc. Vairavan Latha Officer SELL $14.33 89 $1,275 65,015
2025-08-06 01:28 2025-08-04 ARQT Arcutis Biotherapeutics Inc. Matsuda Masaru Officer SELL $14.33 6,330 $90,687 197,364
SHOW ENTRIES

Sector-Wide Insider Alpha

Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.

SEC Filings in Pharmaceutical Preparations

Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.